Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

UCB (EQUASYM worldwide rights)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Portfolio of pharmaceutical rights and patents. The portfolio entails worldwide rights to the instant-release and extended-release versions of Equasym outside the United States, Canada and Barbados. Equasym IR and XL are used for the treatment of attention deficit hyperactivity disorder (ADD).

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Business Products and Services
Other Industries
Other Healthcare
Acquirer
Primary Office
  • Brussels
  • Belgium

UCB (EQUASYM worldwide rights) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore UCB (EQUASYM worldwide rights)‘s full profile, request access.

Request full access to PitchBook

UCB (EQUASYM worldwide rights) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore UCB (EQUASYM worldwide rights)‘s full profile, request access.

Request full access to PitchBook